SCTX Scribe Therapeutics, Inc. Insider Trading

Chief Business Officer Svetlana Lucas purchased 3,000 shares at $15.00 in private placement allocation.

Svetlana Lucas, Chief Business Officer, acquired 3,000 shares at $15.00 on 2026-07-23, representing her initial equity stake in Scribe Therapeutics. This transaction is a private placement allocation, not a discretionary open-market purchase driven by insider conviction. Lucas maintains substantial derivative holdings totaling 228,399 shares across three stock option vehicles (9,547 shares and 109,426 shares in two separate option pools), indicating meaningful long-term incentive participation. The purchase occurred during SCTX's recent IPO window, consistent with early-stage allocation patterns rather than a signal of executive confidence in current valuation.

CFO David Parrot purchases 2,666 shares at $15.00 in SCTX private placement allocation during recent IPO

David Parrot, Chief Financial Officer of Scribe Therapeutics, acquired 2,666 shares through 2 separate purchases at $15.00 on 2026-07-23, investing $39,990.00 total. This transaction is flagged as a private placement allocation, not a discretionary open-market purchase, and therefore does not reflect insider conviction about the stock's direction. Scribe is a recent IPO listing (2 trading days old as of the price reference date), making traditional valuation and conviction-based interpretation inappropriate. Parrot maintains substantial derivative holdings totaling 227,761 shares across three option grants (8,909 and 109,426 shares each across two standard options, plus 109,426 performance-based shares), indicating meaningful longer-term equity alignment with the company's success.